Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

GNPX - Genprex, Inc. So'nggi Yangiliklar | Finranks

Home

/

GNPX

G

Genprex, Inc. (GNPX)

NCM – Real vaqt narxi. Valyuta: USD

4.71

+0.24 (5.44%)

Bozor ochiq: Aug 12, 2026, 11:54 AM EDT

4.47

+0.00 (0.05%)

Oldingi bozordan keyin: Aug 11, 2026, 7:51 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Videolar

No Data

There is no data to display

Press-relizlar

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.